J H Salmon1, A C Rat2, H Achit3, W Ngueyon-Sime4, C Gard5, F Guillemin6, D Jolly7, B Fautrel8. 1. Rheumatology Department, Maison Blanche Hospital, Reims University Hospitals, Reims, F-51092, France; University of Reims Champagne-Ardenne, Faculty of Medicine, EA 3797, Reims F-51095, France. Electronic address: jhsalmon@chu-reims.fr. 2. Rheumatology Department, CHRU de Nancy, Hôpitaux de Brabois, Vandoeuvre-lès-Nancy, France; Université de Lorraine, APEMAC, F-54000 Nancy, France; CHRU-Nancy, INSERM, CIC-EC, 54000 Nancy, France. Electronic address: ac.rat@chru-nancy.fr. 3. Université de Lorraine, APEMAC, F-54000 Nancy, France; CHRU-Nancy, INSERM, CIC-EC, 54000 Nancy, France. Electronic address: h.achit@chru-nancy.fr. 4. Université de Lorraine, APEMAC, F-54000 Nancy, France; CHRU-Nancy, INSERM, CIC-EC, 54000 Nancy, France. Electronic address: w.ngueyon-sime@chru-nancy.fr. 5. Department of Pharmacy, Pitié-Salpêtrière Hospital, 47-83 Boulevard de l'Hôpital, 75013 Paris, France. Electronic address: claudine.gard@aphp.fr. 6. Université de Lorraine, APEMAC, F-54000 Nancy, France; CHRU-Nancy, INSERM, CIC-EC, 54000 Nancy, France. Electronic address: francis.guillemin@chru-nancy.fr. 7. University of Reims Champagne-Ardenne, Faculty of Medicine, EA 3797, Reims F-51095, France; Department of Research and Innovation, Robert Debré Hospital, Reims University Hospitals, Reims F-51092, France. Electronic address: djolly@chu-reims.fr. 8. Sorbonne Université, Institut Pierre Louis de d'Epidémiologie et Santé Publique, GRC08 Paris, France; AP-HP, Pitié-Salpêtrière Hospital, Rheumatology Department, 83 Boulevard de l'Hôpital, 75013 Paris, France. Electronic address: bruno.fautrel@psl.aphp.fr.
Abstract
BACKGROUND: Data on the economic consequences of hip and knee osteoarthritis (OA) are scarce. We aimed to estimate the annual direct and indirect costs for patients followed for hip and/or knee OA in the Knee and Hip Osteoarthritis Long term Assessment (KHOALA) cohort. METHODS: The KHOALA cohort, set up from 2007 to 2009, is a French multicenter study of 878 individuals with symptomatic knee/hip OA who were 40-75 years old. Resources used were collected annually for 5 years. Costs were assigned by using official sources and expressed in 2018 euros per patient. RESULTS: The mean annual total costs per patient over the 5-year study period were 2,180 ± 5,305€. The mean annual direct medical costs per patient were 2,120 ± 5,275€ and mean annual indirect costs per patient 180 ± 1,735€ for people of working age. Costs increased slightly over the study period. Drugs were the largest cost share, representing over 50% of all direct costs. However, the proportion attributable to OA drugs accounted for only 10.5% of drug costs. The second cost share was hospitalizations; hip and knee prosthetic surgery accounted for 27% of surgery hospitalization costs. Health professional visits were the third cost share, accounting for 3% of direct medical costs. The median costs induced could be as high as 2 billion €/year (IQR 0.7-4.3) in France. CONCLUSION: Hip and knee OA costs were substantial and increased over the study period in France. However, the costs attributable to OA represented only a small fraction of overall costs.
BACKGROUND: Data on the economic consequences of hip and knee osteoarthritis (OA) are scarce. We aimed to estimate the annual direct and indirect costs for patients followed for hip and/or knee OA in the Knee and Hip Osteoarthritis Long term Assessment (KHOALA) cohort. METHODS: The KHOALA cohort, set up from 2007 to 2009, is a French multicenter study of 878 individuals with symptomatic knee/hip OA who were 40-75 years old. Resources used were collected annually for 5 years. Costs were assigned by using official sources and expressed in 2018 euros per patient. RESULTS: The mean annual total costs per patient over the 5-year study period were 2,180 ± 5,305€. The mean annual direct medical costs per patient were 2,120 ± 5,275€ and mean annual indirect costs per patient 180 ± 1,735€ for people of working age. Costs increased slightly over the study period. Drugs were the largest cost share, representing over 50% of all direct costs. However, the proportion attributable to OA drugs accounted for only 10.5% of drug costs. The second cost share was hospitalizations; hip and knee prosthetic surgery accounted for 27% of surgery hospitalization costs. Health professional visits were the third cost share, accounting for 3% of direct medical costs. The median costs induced could be as high as 2 billion €/year (IQR 0.7-4.3) in France. CONCLUSION:Hip and knee OA costs were substantial and increased over the study period in France. However, the costs attributable to OA represented only a small fraction of overall costs.
Authors: Justus Gille; Ellen Reiss; Moritz Freitag; Jan Schagemann; Matthias Steinwachs; Tomasz Piontek; Eric Reiss Journal: Orthop J Sports Med Date: 2021-02-26
Authors: Bob J Evers; Martijn H J Van Den Bosch; Arjen B Blom; Peter M van der Kraan; Sander Koëter; Rogier M Thurlings Journal: Front Med (Lausanne) Date: 2022-08-22